GTCR LLC’s Maravai LifeSciences MRVI Stock Holding History

GTCR LLC’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$126M	Hold	20,150,005	–	–	3.22%	3
2026 Q1	$57M	Hold	20,150,005	–	–	1.51%	5
2025 Q4	$65.5M	Hold	20,150,005	–	–	10.88%	3
2025 Q3	$57.8M	Hold	20,150,005	–	–	6.38%	3
2025 Q2	$48.6M	Hold	20,150,005	–	–	5.18%	3
2025 Q1	$44.5M	Hold	20,150,005	–	–	4.99%	3
2024 Q4	$110M	Hold	20,150,005	–	–	10.56%	3
2024 Q3	$167M	Hold	20,150,005	–	–	13.05%	3
2024 Q2	$144M	Sell	20,150,005 -1,531,028	-7%	-$13.2M	12.02%	3
2024 Q1	$188M	Hold	21,681,033	–	–	15.96%	3
2023 Q4	$142M	Hold	21,681,033	–	–	8.62%	3
2023 Q3	$217M	Hold	21,681,033	–	–	13.15%	3
2023 Q2	$269M	Hold	21,681,033	–	–	12.63%	3
2023 Q1	$304M	Hold	21,681,033	–	–	15.02%	3
2022 Q4	$310M	Hold	21,681,033	–	–	18.04%	4
2022 Q3	$554M	Hold	21,681,033	–	–	32.68%	1
2022 Q2	$616M	Hold	21,681,033	–	–	21.97%	2
2022 Q1	$765M	Hold	21,681,033	–	–	24.22%	2
2021 Q4	$908M	Hold	21,681,033	–	–	27.7%	2
2021 Q3	$1.06B	Sell	21,681,033 -2,931,441	-12%	-$143M	26.99%	2
2021 Q2	$1.03B	Sell	24,612,474 -3,034,041	-11%	-$118M	28.61%	2
2021 Q1	$985M	Hold	27,646,515	–	–	27.81%	2
2020 Q4	$775M	Buy	+27,646,515	New	+$770M	19.37%	2

Other funds holding MRVI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

1WCM

12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OAM

Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GTCR LLC's MRVI Position: Q2 2026 in Review

GTCR LLC held its Maravai LifeSciences (MRVI) position steady in Q2 2026 at 20,150,005 shares worth $126M. The position accounts for 3.22% of the portfolio, ranked #3.

GTCR LLC first reported a position in MRVI in Q4 2020 and has held it in 23 quarters since. The position peaked at $1.06B in Q3 2021. 177 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

GTCR LLC held 20,150,005 shares of Maravai LifeSciences worth $126M as of Q2 2026.
GTCR LLC left its Maravai LifeSciences share count unchanged in Q2 2026.
Maravai LifeSciences made up 3.22% of GTCR LLC's portfolio in Q2 2026, its #3 holding.
GTCR LLC first reported a position in Maravai LifeSciences in Q4 2020 and has held it in 23 quarters since.
GTCR LLC's Maravai LifeSciences position peaked at $1.06B in Q3 2021.
177 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on GTCR LLC's 13F filing for Q2 2026, filed 13 Aug 2026.